美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

BRIACELL THERAPEUTICS CORP C/WTS (TO PUR COM) 15/01/2031

0.9600

+0.06006.67%

盤後：0.96000.00000.00%16:18 EDT

成交量：5.74萬

成交額：5.22萬

市值：- -

市盈率：- -

高：0.9900

開：0.9800

低：0.8850

收：0.9000

52周最高：1.40

52周最低：0.6100

股本：- -

流通股本：- -

量比：3.85

換手率：- -

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

Briacell啓動加拿大首個臨床站點——Sunnybrook，用於轉移性乳腺癌關鍵性III期試驗

Briacell與富士膠片生物技術加州公司就Bria-IMT達成生產協議

Briacell公司達成生產協議，為三期臨床及商業化量產鋪路

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/BCTXL/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BCTXL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCTXL\",,,,,undefined,":{"symbol":"BCTXL","market":"US","secType":"STK","nameCN":"BRIACELL THERAPEUTICS CORP C/WTS (TO PUR COM) 15/01/2031","latestPrice":0.96,"timestamp":1787688000000,"preClose":0.9,"halted":0,"volume":57360,"hourTrading":{"tag":"盘后","latestPrice":0.96,"preClose":0.96,"latestTime":"16:18 EDT","volume":2412,"amount":2315.52,"timestamp":1787689114887,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0666666666666666,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":0.06,"latestTime":"08-25 16:00:00 EDT","open":0.98,"high":0.99,"low":0.884999,"amount":52200,"amplitude":0.116668,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1787731200000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":0.9,"postHourTrading":{"tag":"盘后","latestPrice":0.96,"preClose":0.96,"latestTime":"16:18 EDT","volume":2412,"amount":2315.52,"timestamp":1787689114887,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":3.845174},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCTXL\",,,,,undefined,":{"symbol":"BCTXL","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":3.845174,"shares":0,"dividePrice":0,"high":0.99,"amplitude":0.116668,"preClose":0.9,"low":0.884999,"week52Low":0.61,"pbRate":"--","week52High":1.4,"institutionHeld":0,"latestPrice":0.96,"eps":0,"divideRate":0,"volume":57360,"delay":0,"ttmEps":0,"open":0.98,"prevYearClose":0.65,"prevWeekClose":1.09,"prevMonthClose":0.92,"prevQuarterClose":0.89,"fiveDayClose":0.84,"twentyDayClose":0.82,"sixtyDayClose":0.95},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCTXL\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCTXL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCTXL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCTXL\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1197584324","title":"Briacell啓動加拿大首個臨床站點——Sunnybrook，用於轉移性乳腺癌關鍵性III期試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1197584324","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197584324?lang=zh_tw&edition=fundamental","pubTime":"2026-07-16 19:37","pubTimestamp":1784201833,"startTime":"0","endTime":"0","summary":"Briacell Therapeutics Corp. 已正式启动其在加拿大的首个临床研究中心——位于多伦多的Sunnybrook健康科学中心，以推进其针对转移性乳腺癌的关键性III期临床试验。这一进展标志着该公司核心候选疗法Bria-IMT™联合检查点抑制剂的研究进入了一个重要阶段，旨在评估其在难治性转移性乳腺癌患者中的安全性与有效性。Sunnybrook作为加拿大顶尖的癌症研究与治疗机构之一，其参与有望加速患者招募并增强试验数据的权威性。此次III期试验的成功与否，对Briacell的未来商业化前景及股价走势可能产生深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTXZ","BCTXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116025944","title":"Briacell與富士膠片生物技術加州公司就Bria-IMT達成生產協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1116025944","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116025944?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 19:34","pubTimestamp":1784115281,"startTime":"0","endTime":"0","summary":"Briacell Therapeutics Corp宣布，已与富士胶片生物技术加州公司就其实验性癌症免疫疗法Bria-IMT达成了生产安排。该协议旨在为Bria-IMT的临床开发和未来潜在的商业化提供支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTXZ","BCTXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107769441","title":"Briacell公司達成生產協議，為三期臨床及商業化量產鋪路","url":"https://stock-news.laohu8.com/highlight/detail?id=1107769441","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107769441?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 19:33","pubTimestamp":1784115213,"startTime":"0","endTime":"0","summary":"Briacell Therapeutics Corp宣布达成一项关键的生产安排。此举旨在确保其候选疗法在关键三期临床研究阶段拥有充足的生产能力，并为未来潜在的大规模商业化生产奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTXL","BCTXZ"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}]}}